[Clinical assessment of dysarthria: presentation and validation of a method].
We adapted in French the Frenchay Dysarthria Assessment (FDA) developed by P. Enderby in 1983. This tool quantitatively evaluates the organs involved in speech and provides a measurement of intelligibility. Productions of normal subjects were analyzed. Reproductibility of data (correlation and interobserver concordance) was high in 18 dysarthric patients. A study performed in 100 dysarthric patients corresponding to 4 types of dysarthria (spastic, ataxic, hypokinetic and mixte) showed that dysarthria resulted from a global impairment of organs implied in speech, rather than one specific organ. The reduction in the intelligibility score was related to organ impairment.
Service de Neurophysiologie, CHU, Rouen et Inserm U320, Caen.
P
P
Auzou
C
C
Ozsancak
M
M
Jan
S
S
Léonardon
J F
JF
Ménard
M J
MJ
Gaillard
F
F
Eustache
D
D
Hannequin
D000368:Aged; D004401:Dysarthria / Q000145:classification / Q000503:physiopathology / Q000523:psychology*; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D012016:Reference Values; D015203:Reproducibility of Results; D013063:Speech Discrimination Tests; D013065:Speech Intelligibility
Evaluation clinique de la dysarthrie: présentation et validation d'une méthode.